Oramed Pharmaceuticals
ORMP
23 hedge funds and large institutions have $1.34M invested in Oramed Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
47% more capital invested
Capital invested by funds: $910K → $1.34M (+$431K)
10% more funds holding
Funds holding: 21 → 23 (+2)
0.23% more ownership
Funds ownership: 1.12% → 1.35% (+0.23%)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
88% less call options, than puts
Call options by funds: $4K | Put options by funds: $34K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$189K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$121K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$4.71K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$90K |
| 2 |
PCM
Penserra Capital Management
Orinda,
California
|
-$25K |
| 3 |
CG
Cutler Group
San Francisco,
California
|
-$9.05K |
| 4 |
Morgan Stanley
New York
|
-$2.99K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$626 |
ORMP Hedge Fund Activity: Q2 2017 in Review
23 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q2 2017, worth a combined $1.34M — up 47% from $910K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ORMP positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $189K. The largest seller was Acrospire Investment Management, exiting entirely with an estimated $90K sold.
- 23 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q2 2017, up from 21 in Q1 2017.
- Funds reported $1.34M of Oramed Pharmaceuticals stock for Q2 2017, up 47% quarter-over-quarter.
- 4 funds opened new Oramed Pharmaceuticals positions in Q2 2017 and 2 closed out, a net change of +2 holders.
- The largest Oramed Pharmaceuticals buyer in Q2 2017 was Renaissance Technologies, an estimated $189K added.
- The largest Oramed Pharmaceuticals seller in Q2 2017 was Acrospire Investment Management, an estimated $90K sold.
Based on aggregated 13F filings for Q2 2017.